Table 3 IgG levels to P. falciparum antigens not included in RTS,S/AS02_A and protection against the first or only episode of clinical malaria 6 months post-vaccination in all children

	Hazard ratio (95% CI)	p-value	N children N events	Hazard ratio (95% CI)	p-value	N children N events
IgG levels	Manhiça children			Manhiça and Ilha Josina children
PfMSP5 M3	0.84 (0.71–1.00)	0.050	713	0.83 (0.72–0.96)	0.011	838
PfMSP5 M0	1.48 (1.26–1.74)	2.5e-6	163	1.29 (1.12–1.49)	0.0005	225
PfMSP1 Bl2 M3	0.76 (0.59–0.98)	0.037	710	0.78 (0.64–0.96)	0.021	836
PfMSP1 Bl2 M0	1.57 (1.20–2.05)	0.001	162	1.23 (0.98–1.54)	0.076	224
PfRh5 M3	0.77 (0.58–1.03)	0.075	713	0.79 (0.62–1.01)	0.056	839
PfRh5 M0	1.59 (1.15–2.21)	0.006	163	1.22 (0.93–1.61)	0.155	225
PfRh4.2 M3	0.84 (0.65–1.09)	0.200	713	0.83 (0.68–1.01)	0.060	838
PfRh4.2 M0	1.29 (1.02–1.64)	0.035	163	1.04 (0.85–1.27)	0.692	224
PfEBA140 M3	0.86 (0.65–1.12)	0.260	710	0.83 (0.68–1.02)	0.072	836
PfEBA140 M0	1.45 (1.11–1.89)	0.006	162	1.16 (0.94–1.42)	0.166	224
PfEXP1 M3	1.14 (0.96–1.34)	0.131	710	1.09 (0.94–1.25)	0.252	836
PfEXP1 M0	1.18 (1.02–1.37)	0.024	162	1.11 (0.98–1.26)	0.101	224
PfMSP2 M3	1.09 (0.93–1.28)	0.281	711	1.07 (0.94–1.23)	0.302	836
PfMSP2 M0	1.21 (1.04–1.41)	0.016	163	1.12 (0.98–1.27)	0.091	224
PfEMP1 M3	0.92 (0.66–1.30)	0.643	709	0.89 (0.71–1.13)	0.333	835
PfEMP1 M0	1.54 (1.11–2.12)	0.009	163	1.20 (0.94–1.53)	0.138	225

Cox proportional hazards regression model adjusted by baseline (month [M]0) IgG levels to the respective antigens, by post-vaccination PfCSP NANP IgG levels and by age at baseline. Models with both cohorts combined were also adjusted by site, where Manhiça was independently associated with protection (Hazard ratio ∼0.3, p < 0.001).
M month, CI confidence intervals, N number of children and events of clinical malaria.

Quick links

Search